Rapid regression of microsatellite instability-high/programmed cell death ligand 1-negative recurrent endometrial carcinoma by immune checkpoint blockade with pembrolizumab: A case report and literature review
In a 53-year-old woman who had a surgical diagnosis of grade 3 endometrioid carcinoma (pT1aN0M0, FIGO 1A), adjuvant chemotherapy with paclitaxel and carboplatin was initiated. However, after the completion of fourth cycle, the patient refused to continue the treatment. At 12 months after surgery, lo...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-05-01
|
| Series: | Gynecologic Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352578920300199 |
| _version_ | 1818876219405369344 |
|---|---|
| author | Akihiro Takeda Wataru Koike Kazuko Watanabe |
| author_facet | Akihiro Takeda Wataru Koike Kazuko Watanabe |
| author_sort | Akihiro Takeda |
| collection | DOAJ |
| description | In a 53-year-old woman who had a surgical diagnosis of grade 3 endometrioid carcinoma (pT1aN0M0, FIGO 1A), adjuvant chemotherapy with paclitaxel and carboplatin was initiated. However, after the completion of fourth cycle, the patient refused to continue the treatment. At 12 months after surgery, local recurrence was noted near the left posterior portion of the vaginal stump. External radiotherapy to the pelvic cavity achieved marked reduction of the tumor. At 12 months after radiotherapy, regrowth of the tumor was noted. Although the tumor was negative for programmed cell death ligand 1, after the identification of a high level of microsatellite instability, treatment with pembrolizumab, an immune checkpoint inhibitor, was initiated. After 2 cycles of treatment, the recurrent tumor markedly regressed. Four months later, a complete metabolic response was confirmed by positron emission tomography, without any immune-related adverse events; at the time of writing, this has been maintained for 9 months. |
| first_indexed | 2024-12-19T13:38:55Z |
| format | Article |
| id | doaj.art-be6f9d9894064cd6acf43c277747a9a9 |
| institution | Directory Open Access Journal |
| issn | 2352-5789 |
| language | English |
| last_indexed | 2024-12-19T13:38:55Z |
| publishDate | 2020-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gynecologic Oncology Reports |
| spelling | doaj.art-be6f9d9894064cd6acf43c277747a9a92022-12-21T20:19:05ZengElsevierGynecologic Oncology Reports2352-57892020-05-0132Rapid regression of microsatellite instability-high/programmed cell death ligand 1-negative recurrent endometrial carcinoma by immune checkpoint blockade with pembrolizumab: A case report and literature reviewAkihiro Takeda0Wataru Koike1Kazuko Watanabe2Department of Obstetrics & Gynecology, Gifu Prefectural Tajimi Hospital, 5-161 Maebata-cho, Tajimi, Gifu 507-8522, Japan; Corresponding author.Department of Radiology, Gifu Prefectural Tajimi Hospital, 5-161 Maebata-cho, Tajimi, Gifu 507-8522, JapanDepartment of Diagnostic Pathology, Gifu Prefectural Tajimi Hospital, 5-161 Maebata-cho, Tajimi, Gifu 507-8522, JapanIn a 53-year-old woman who had a surgical diagnosis of grade 3 endometrioid carcinoma (pT1aN0M0, FIGO 1A), adjuvant chemotherapy with paclitaxel and carboplatin was initiated. However, after the completion of fourth cycle, the patient refused to continue the treatment. At 12 months after surgery, local recurrence was noted near the left posterior portion of the vaginal stump. External radiotherapy to the pelvic cavity achieved marked reduction of the tumor. At 12 months after radiotherapy, regrowth of the tumor was noted. Although the tumor was negative for programmed cell death ligand 1, after the identification of a high level of microsatellite instability, treatment with pembrolizumab, an immune checkpoint inhibitor, was initiated. After 2 cycles of treatment, the recurrent tumor markedly regressed. Four months later, a complete metabolic response was confirmed by positron emission tomography, without any immune-related adverse events; at the time of writing, this has been maintained for 9 months.http://www.sciencedirect.com/science/article/pii/S2352578920300199Endometrial carcinomaImmune checkpoint inhibitorMicrosatellite instabilityPembrolizumabProgrammed cell death 1 |
| spellingShingle | Akihiro Takeda Wataru Koike Kazuko Watanabe Rapid regression of microsatellite instability-high/programmed cell death ligand 1-negative recurrent endometrial carcinoma by immune checkpoint blockade with pembrolizumab: A case report and literature review Gynecologic Oncology Reports Endometrial carcinoma Immune checkpoint inhibitor Microsatellite instability Pembrolizumab Programmed cell death 1 |
| title | Rapid regression of microsatellite instability-high/programmed cell death ligand 1-negative recurrent endometrial carcinoma by immune checkpoint blockade with pembrolizumab: A case report and literature review |
| title_full | Rapid regression of microsatellite instability-high/programmed cell death ligand 1-negative recurrent endometrial carcinoma by immune checkpoint blockade with pembrolizumab: A case report and literature review |
| title_fullStr | Rapid regression of microsatellite instability-high/programmed cell death ligand 1-negative recurrent endometrial carcinoma by immune checkpoint blockade with pembrolizumab: A case report and literature review |
| title_full_unstemmed | Rapid regression of microsatellite instability-high/programmed cell death ligand 1-negative recurrent endometrial carcinoma by immune checkpoint blockade with pembrolizumab: A case report and literature review |
| title_short | Rapid regression of microsatellite instability-high/programmed cell death ligand 1-negative recurrent endometrial carcinoma by immune checkpoint blockade with pembrolizumab: A case report and literature review |
| title_sort | rapid regression of microsatellite instability high programmed cell death ligand 1 negative recurrent endometrial carcinoma by immune checkpoint blockade with pembrolizumab a case report and literature review |
| topic | Endometrial carcinoma Immune checkpoint inhibitor Microsatellite instability Pembrolizumab Programmed cell death 1 |
| url | http://www.sciencedirect.com/science/article/pii/S2352578920300199 |
| work_keys_str_mv | AT akihirotakeda rapidregressionofmicrosatelliteinstabilityhighprogrammedcelldeathligand1negativerecurrentendometrialcarcinomabyimmunecheckpointblockadewithpembrolizumabacasereportandliteraturereview AT watarukoike rapidregressionofmicrosatelliteinstabilityhighprogrammedcelldeathligand1negativerecurrentendometrialcarcinomabyimmunecheckpointblockadewithpembrolizumabacasereportandliteraturereview AT kazukowatanabe rapidregressionofmicrosatelliteinstabilityhighprogrammedcelldeathligand1negativerecurrentendometrialcarcinomabyimmunecheckpointblockadewithpembrolizumabacasereportandliteraturereview |